Coalterations of p53 and PTEN tumor suppressor genes in non-small cell lung carcinoma patients

被引:27
作者
Andjelkovic, Tijana
Bankovic, Jasna
Stojsic, Jelena
Milinkovic, Vedrana
Podolski-Renic, Ana
Ruzdijic, Sabera
Tanic, Nikola [1 ]
机构
[1] Univ Belgrade, Dept Neurobiol, Inst Biol Res, Belgrade 11060, Serbia
关键词
MICROSATELLITE INSTABILITY; METHYLATION STATUS; HUMAN BRAIN; CANCER; MUTATIONS; EXPRESSION; HETEROZYGOSITY; PTEN/MMAC1; INACTIVATION; ACTIVATION;
D O I
10.1016/j.trsl.2010.09.004
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
The inactivation of p53 and PTEN tumor suppressor genes is a common genetic event in lung cancer. However, data on the effect of the joint inactivation of tumor-suppressor genes in non-small cell lung carcinoma (NSCLC) are lacking. The purpose of this study was to investigate the alterations in PTEN and p53 genes, as well as to evaluate their mutual role in NSCLC pathogenesis and their impact on survival rate. To that end, polymerase chain reaction single-strand conformational polymorphism (PCR-SSCP), sequencing, methylation-specific PCR, and fragment analysis were used. The results obtained were correlated with clinicopathologic parameters, the level of genomic instability, and patient survival. Overall, 13% of specimens had aberrant p53 only, 13% had inactive PTEN only, and 50% of samples had both genes altered. Correlation analyses showed that the mutual inactivation of p53 and PTEN was a frequent event that was associated significantly with the increased level of genomic instability and lymph node invasion implying their synergistic effect in promoting metastatic phenotype of this kind of cancer. In addition, our results revealed a significant association of joint alterations of these genes with dramatically shortened survival indicating that aberrant p53 and PTEN could be used as an adverse prognostic factor for NSCLC patients' outcome. Our findings established the relevance of the combinatorial inactivation of p53 and PTEN in NSCLC progression and identified a subgroup of patients with a particularly aggressive disease. (Translational Research 2011;157:19-28)
引用
收藏
页码:19 / 28
页数:10
相关论文
共 46 条
[1]   Synergistic effects of the purine analog sulfinosine and curcumin on the multidrug resistant human non-small cell lung carcinoma cell line (NCI-H460/R) [J].
Andjelkovic, Tijana ;
Pesic, Milica ;
Bankovic, Jasna ;
Tanic, Nikola ;
Markovic, Ivanka D. ;
Ruzdijic, Sabera .
CANCER BIOLOGY & THERAPY, 2008, 7 (07) :1024-1032
[2]  
[Anonymous], 2004, Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs
[3]   Identification of genes associated with non-small-cell lung cancer promotion and progression [J].
Bankovic, Jasna ;
Stojsic, Jelena ;
Jovanovic, Dragana ;
Andjelkovic, Tijana ;
Milinkovic, Vedrana ;
Ruzdijic, Sabera ;
Tanic, Nikola .
LUNG CANCER, 2010, 67 (02) :151-159
[4]  
Campling Barbara G, 2003, Methods Mol Med, V75, P53
[5]  
CARBONE D, 1991, ONCOGENE, V6, P1691
[6]  
Catasus LI, 2009, MODERN PATHOL, V22, p208A
[7]   Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis [J].
Chen, ZB ;
Trotman, LC ;
Shaffer, D ;
Lin, HK ;
Dotan, ZA ;
Niki, M ;
Koutcher, JA ;
Scher, HI ;
Ludwig, T ;
Gerald, W ;
Cordon-Cardo, C ;
Pandolfi, PP .
NATURE, 2005, 436 (7051) :725-730
[8]   Novel Mutations of the Suppressor Gene PTEN in Colorectal Carcinomas Stratified by Microsatellite Instability- and TP53 Mutation- Status [J].
Danielsen, Stine A. ;
Lind, Guro E. ;
Bjornslett, Merete ;
Meling, Gunn I. ;
Rognum, Torleiv O. ;
Heim, Sverre ;
Lothe, Ragnhild A. .
HUMAN MUTATION, 2008, 29 (11) :E252-E262
[9]   Analysis of PTEN and the 10q23 region in primary prostate carcinomas [J].
Feilotter, HE ;
Nagai, MA ;
Boag, AH ;
Eng, C ;
Mulligan, LM .
ONCOGENE, 1998, 16 (13) :1743-1748
[10]   PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms [J].
Freeman, DJ ;
Li, AG ;
Wei, G ;
Li, HH ;
Kertesz, N ;
Lesche, R ;
Whale, AD ;
Martinez-Diaz, H ;
Rozengurt, N ;
Cardiff, RD ;
Liu, X ;
Wu, H .
CANCER CELL, 2003, 3 (02) :117-130